Evidence map›Paper›PMID 26733066›Full record

ArticlemBio2016

Corynebacterium accolens Releases Antipneumococcal Free Fatty Acids from Human Nostril and Skin Surface Triacylglycerols.

Lindsey Bomar, Silvio D Brugger, Brian H Yost, Sean S Davies, Katherine P Lemon

Open access · goldAbstract read
In one paragraph

Article in mBio, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 209 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
209citing papers in PubMed, 3 pooled it
23.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

209 citing papers in PubMed, 3 syntheses or guidelines pooled it, 345 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Observational
  10. Review
  11. Review
  12. Review
  13. Anaerobe-Driven Inflammation and Epithelial Barrier Disruption in Genital HIV Acquisition.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026
    Review
  14. Association of nasopharyngealMicrobiology spectrum · 2026
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

149 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Lindsey BomarDepartment of Microbiology, The Forsyth Institute, Cambridge, Massachusetts, USA Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, Massachusetts, USA.
Silvio D BruggerDepartment of Microbiology, The Forsyth Institute, Cambridge, Massachusetts, USA Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, Massachusetts, USA.
Brian H YostDepartment of Microbiology, The Forsyth Institute, Cambridge, Massachusetts, USA.
Sean S DaviesDepartment of Pharmacology, Division of Clinical Pharmacology, Vanderbilt University, Nashville, Tennessee, USA.
Katherine P LemonDepartment of Microbiology, The Forsyth Institute, Cambridge, Massachusetts, USA Division of Infectious Diseases, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA klemon@forsyth.org.
Harvard University · USBoston Children's Hospital · USVanderbilt University · US

Funding

HARVARD CLINICAL AND TRANSLATIONAL SCIENCE CENTER (UL1)UL1RR025758 · NCRR · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2008 to 2011
$91.4M
Post-PCV pneumococcal population genetics and resistanceR01AI066304 · NIAID · HARVARD PILGRIM HEALTH CARE, INC. · PI FINKELSTEIN, JONATHAN A · 2006 to 2014
$6.4M
Antibiotics from nose and throat commensals that impact pathogen colonizationR01AI101018 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI FISCHBACH, MICHAEL ANDREW, LEMON, KATHERINE PAIGE · 2012 to 2021
$4.4M
FORSYTH POSTDOCTORAL TRAINING IN ORAL HEALTH RESEARCHT32DE007327 · NIDCR · FORSYTH INSTITUTE · PI VAN DYKE, THOMAS ELLIOTT · 2001 to 2015
$3.5M
The Forsyth Core Center for Discovery at the Host-Biofilm InterfaceP30DE020751 · NIDCR · ADA FORSYTH INSTITUTE, INC. · PI SMITH, DANIEL JAMES · 2009 to 2010
$1.8M
Therapeutically Modified Gut Bacteria for Treatment of ObesityR01AT007830 · NCCIH · VANDERBILT UNIVERSITY · PI DAVIES, SEAN STEPHEN · 2013 to 2017
$1.8M
NCCIH NIH HHS AT007830NCCIH NIH HHS R01 AT007830NCRR NIH HHS 1 UL1 RR025758-02NCRR NIH HHS UL1 RR025758NIAID NIH HHS AI066304NIAID NIH HHS AI101018NIAID NIH HHS R01 AI066304NIAID NIH HHS R01 AI101018NIDCR NIH HHS DE007327NIDCR NIH HHS DE020751NIDCR NIH HHS P30 DE020751NIDCR NIH HHS T32 DE007327
6 · The paper itself

Abstract

unlabelledBacterial interspecies interactions play clinically important roles in shaping microbial community composition. We observed that Corynebacterium spp. are overrepresented in children free of Streptococcus pneumoniae (pneumococcus), a common pediatric nasal colonizer and an important infectious agent. Corynebacterium accolens, a benign lipid-requiring species, inhibits pneumococcal growth during in vitro cocultivation on medium supplemented with human skin surface triacylglycerols (TAGs) that are likely present in the nostrils. This inhibition depends on LipS1, a TAG lipase necessary for C. accolens growth on TAGs such as triolein. We determined that C. accolens hydrolysis of triolein releases oleic acid, which inhibits pneumococcus, as do other free fatty acids (FFAs) that might be released by LipS1 from human skin surface TAGs. Our results support a model in which C. accolens hydrolyzes skin surface TAGS in vivo releasing antipneumococcal FFAs. These data indicate that C. accolens may play a beneficial role in sculpting the human microbiome. IMPORTANCE: Little is known about how harmless Corynebacterium species that colonize the human nose and skin might impact pathogen colonization and proliferation at these sites. We show that Corynebacterium accolens, a common benign nasal bacterium, modifies its local habitat in vitro as it inhibits growth of Streptococcus pneumoniae by releasing antibacterial free fatty acids from host skin surface triacylglycerols. We further identify the primary C. accolens lipase required for this activity. We postulate a model in which higher numbers of C. accolens cells deter/limit S. pneumoniae nostril colonization, which might partly explain why children without S. pneumoniae colonization have higher levels of nasal Corynebacterium. This work narrows the gap between descriptive studies and the needed in-depth understanding of the molecular mechanisms of microbe-microbe interactions that help shape the human microbiome. It also lays the foundation for future in vivo studies to determine whether habitat modification by C. accolens could be promoted to control pathogen colonization.

Indexed as

AntibiosisAnti-Bacterial AgentsCarrier StateChildChild, PreschoolCorynebacteriumFatty Acids, NonesterifiedHumansHydrolysisInfantMicrobiotaNasal CavityPneumococcal InfectionsSkinStreptococcus pneumoniaeTriglyceridesAnti-Bacterial AgentsFatty Acids, NonesterifiedTriglyceridesTriolein

Identifiers

PMID26733066
PMCPMC4725001
OpenAlexW2223503000

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.